Each capsule contains Tranexamic acid 250 mg.
Fibrinolysis, degradation of fibrin in physiological or pathological state, is relating to the outbreak, development and cure of morbid phenomenon, including reactions in vivo caused by plasmin such as the influence on vascular permeability and coagulation factors.
Transic inhibits plasmin activity and shows antihemorrhagic.
Pharmacology: Antiplasminic activity: Transic inhibits both actions of plasminogen activator and plasmin. Antiplasminic activity of Transic is proved by various measurements in vitro, and by determinations of plasmin activity in the blood and local activity after administering to the human body as well.
Hemostatic activity: Transic prevents degradation of fibrin, degeneration of platelet, increase of vascular fragility and splitting of coagulation factors. These effects are clinically proved by reduction of bleeding amount, shortening of bleeding time and bleeding period in days.
Abnormal bleeding and its symptoms in hemorrhagic diseases (purpura, aplastic anemia, cancer, leukemia etc.); Bloody sputum and hemoptosis in pulmonary tuberculosis; Renal bleeding; Genital bleeding; Bleeding in prostatomegaly; Abnormal bleeding during operation.
Transic: Usual oral dose for adult 1-2 capsules 3 times a day.
Dosage of Transic should be individualized in accordance with patient's age and clinical condition.
Gastrointestinal disturbances, nausea, vomiting, anorexia, exanthema, and headache may occur in oral administration. These symptoms disappear by reducing the dose or discontinuing the administration.
Store in tight container. Store below 30°C.
B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.
Transic cap 250 mg
100's;500's
Sign Out
Continue with Google
Sign Up With Email
Already a member?
Sign In
